34.1 Acute Infectious Diarrhea & Gastroenteritis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

34.1 Acute Infectious Diarrhea & Gastroenteritis

Key Takeaways Explain This Topic AI

Diarrhea is clinically staged by duration: Acute (<14 days), Persistent (14-30 days), and Chronic (>30 days); non-inflammatory watery diarrhea involves small bowel enterotoxin hypersecretion without mucosal destruction, whereas inflammatory dysentery involves colonic invasion characterized by fever, tenesmus, hematochezia, and elevated fecal lactoferrin.

Diagnostic stool evaluation (multiplex GI pathogen PCR panel, stool culture, and C. difficile testing) is indicated for severe illness (fever ≥38.5°C, severe volume depletion, hemodynamic instability), gross dysentery, symptoms lasting >7 days, immunocompromised status, or high-risk epidemiologic settings (food handlers, daycares, healthcare workers).

In Shiga toxin-producing Escherichia coli (STEC / E. coli O157:H7) infection, both antimicrobial therapy and antimotility agents (e.g., loperamide) are strictly contraindicated because antibiotic-induced bacterial stress triggers explosive Shiga toxin (Stx1/Stx2) release, dramatically increasing the risk of life-threatening Hemolytic Uremic Syndrome (HUS: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure).

First-line therapy for Clostridioides difficile infection (CDI) is oral fidaxomicin (200 mg BID for 10 days) or oral vancomycin (125 mg QID for 10 days); oral metronidazole is no longer recommended as first-line therapy due to significantly inferior cure rates and higher recurrence rates.

Traveler's diarrhea is most commonly caused by enterotoxigenic E. coli (ETEC); oral azithromycin (1,000 mg single dose or 500 mg daily for 3 days) is the preferred first-line empiric antimicrobial for dysentery, invasive diarrhea, or travel to South/Southeast Asia where fluoroquinolone-resistant Campylobacter is endemic.

Last updated: September 2026

Definitions & Temporal Staging of Diarrhea

Diarrhea is clinically defined as the passage of three or more loose, unformed, or liquid stools per day, or a daily stool output exceeding 200 grams. In ambulatory family medicine, establishing the precise duration of symptoms is the critical first branching point in clinical decision-making, guiding the threshold for diagnostic testing versus supportive observation.

Chronological Staging

Acute Diarrhea (<14 Days Duration) :

Predominantly infectious in origin (viruses, bacteria, protozoa) or related to acute foodborne enterotoxin ingestion, acute medication initiation, or dietary indiscretion.

The vast majority of episodes in immunocompetent hosts are self-limited, resolving within 3 to 7 days without requiring diagnostic stool testing or antimicrobial therapy.

Persistent Diarrhea (14 to 30 Days Duration) :

Frequently caused by persistent protozoal infections ( Giardia duodenalis , Cryptosporidium , Cystoisospora belli ), post-infectious disaccharidase (lactase) deficiency, or post-infectious irritable bowel syndrome (PI-IBS).

Merits targeted diagnostic evaluation, including microscopic examination for ova and parasites (O&P) and selective stool antigen or molecular assays.

Chronic Diarrhea (>30 Days Duration) :

Non-infectious etiologies predominate, including inflammatory bowel disease (IBD; ulcerative colitis, Crohn disease), celiac disease, microscopic colitis, irritable bowel syndrome (IBS-D), malabsorption syndromes, chronic medication side effects, or neuroendocrine neoplasms.

Non-Inflammatory (Watery) vs. Inflammatory (Dysenteric) Diarrhea

Infectious gastroenteritis falls into two major pathophysiological categories based on anatomical localization, mucosal invasion, and inflammatory response.

Clinical and Pathophysiologic Comparison

Clinical Parameter Non-Inflammatory (Watery / Secretory) Diarrhea Inflammatory / Invasive Diarrhea (Dysentery)

Primary Anatomical Site Proximal small intestine (duodenum, jejunum, ileum) Colon and distal ileum (large bowel)

Stool Characteristics High-volume, watery, liquid stools; absence of gross blood or visible purulent mucus Frequent, small-to-moderate volume stools; bloody (hematochezia), mucoid, purulent

Cardinal Symptoms Nausea, prominent early emesis, periumbilical crampy pain, severe dehydration risk Severe lower abdominal cramping, tenesmus (painful rectal urgency), high spiking fevers

Fecal Inflammatory Markers Negative for fecal leukocytes; normal fecal lactoferrin and calprotectin Positive for fecal leukocytes; markedly elevated fecal lactoferrin and calprotectin

Underlying Mechanism Enterotoxin-mediated hypersecretion (cAMP, cGMP, intracellular calcium) or villus blunting without mucosal destruction Direct epithelial cytotoxin invasion, cellular necrosis, mucosal ulceration, acute neutrophilic infiltration

Classic Pathogens Viral : Norovirus, Rotavirus, Enteric Adenovirus, Astrovirus; Bacterial : Enterotoxigenic E. coli (ETEC), Vibrio cholerae ; Foodborne Pre-formed Toxins : Staphylococcus aureus , Bacillus cereus , Clostridium perfringens ; Parasitic : Giardia duodenalis , Cryptosporidium parvum Bacterial : Campylobacter jejuni , Non-typhoidal Salmonella enterica , Shigella species, Shiga toxin-producing E. coli (STEC), Clostridioides difficile , Yersinia enterocolitica ; Parasitic : Entamoeba histolytica (amebic dysentery)

Incubation Windows, Exposure History & Pathogen Profiles

A detailed dietary and exposure history provides high-yield diagnostic clues before laboratory confirmation is available. INCUBATION WINDOWS & FOOD EXPOSURES

[1 to 6 Hours] ─────────> Pre-formed Enterotoxin Ingestion
Staphylococcus aureus (mayonnaise, dairy, meats)
Bacillus cereus emetic toxin (fried rice)
Intense emesis, minimal or no fever

[8 to 16 Hours] ─────────> Ingested Inoculum Toxins (In Vivo Production)
Clostridium perfringens (buffet meats, gravies)
Bacillus cereus diarrheal toxin (vegetables, meats)
Moderate watery diarrhea, crampy periumbilical pain

[16 to 72 Hours] ────────> Bacterial Multiplication & Mucosal Action
ETEC (Traveler's diarrhea: contaminated water/produce)
Salmonella (poultry, raw eggs, reptiles, pet turtles)
Campylobacter jejuni (undercooked chicken, unpasteurized milk)
Shigella (person-to-person, daycares; very low inoculum)

[2 to 8 Days] ─────────> Invasive / Cytotoxic Manifestations
STEC (E. coli O157:H7: undercooked beef, leafy greens)
Yersinia enterocolitica (pork chitterlings; pseudoappendicitis)
Cryptosporidium / Giardia (untreated water, public pools)
Key Pathogens Encountered in Family Medicine

Norovirus : The leading cause of acute gastroenteritis outbreaks across all age groups worldwide. Highly contagious (infectious dose <20 virions) and spread via vomiting aerosols, direct person-to-person contact, and contaminated fomites or shellfish. Characterized by sudden, explosive projectile vomiting, concurrent watery diarrhea, and low-grade fevers in closed communities (cruise ships, schools, nursing homes, hospitals). Resolves spontaneously within 24 to 48 hours.

Rotavirus : Historically the most common cause of severe, dehydrating infantile gastroenteritis before widespread implementation of the live oral rotavirus vaccine (administered at 2, 4, and 6 months of age). Produces significant vomiting followed by copious watery diarrhea and rapid volume depletion in children aged 6 to 24 months.

Campylobacter jejuni : Most common bacterial cause of gastroenteritis in developed nations. Acquired from undercooked poultry or unpasteurized dairy. Manifests with high fevers, rigors, periumbilical pain, and bloody stools. Notably causes pseudoappendicitis (acute right lower quadrant pain and mesenteric adenitis mimicking appendicitis). Recognized as the leading antecedent infectious trigger for Guillain-Barré syndrome (via molecular mimicry between Campylobacter lipooligosaccharides and human peripheral nerve gangliosides GM1) and reactive arthritis (HLA-B27).

Non-Typhoidal Salmonella enterica : Transmitted via undercooked eggs, poultry, contaminated produce, and exotic pets (reptiles, amphibians, turtles). Causes inflammatory diarrhea with fever, cramps, and bacteremia risk. Routine antibiotic therapy in uncomplicated immunocompetent hosts is contraindicated because it prolongs fecal bacterial shedding and does not shorten symptom duration. Antibiotics (oral ciprofloxacin or azithromycin, or IV ceftriaxone) are strictly indicated for high-risk patients: infants <3 months, adults ≥50 years with suspected atherosclerosis (risk of endovascular grafting/mycotic aneurysm), immunocompromised hosts (HIV, sickle cell disease, malignancy), or severe sepsis.

Shigella (S. sonnei, S. flexneri, S. dysenteriae) : Extremely low infectious inoculum (10 to 100 organisms). Transmitted readily via fecal-oral route in child care centers and among men who have sex with men (MSM). Causes hallmark severe tenesmus, high spiking fevers, and frequent, small-volume stools laden with blood, mucus, and sloughed mucosa.

Giardia duodenalis (G. lamblia) : Flagellated protozoan acquired by drinking untreated wilderness stream/well water or from child care exposures. Inhabits the duodenum and upper jejunum, causing epithelial brush border blunting without mucosal ulceration. Clinical hallmark: persistent watery, greasy, foul-smelling, floating stools accompanied by profound sulfurous belching, bloating, flatulence, and epigastric cramping lasting >1 to 2 weeks. Treated with oral tinidazole (2 g single dose) or oral metronidazole (250 to 500 mg TID for 5 to 7 days).

Clinical Indications for Diagnostic Stool Testing

Most acute, mild-to-moderate watery diarrhea in healthy outpatients requires zero laboratory evaluation. Unnecessary stool testing exposes healthcare systems to significant costs without altering clinical management.

When Diagnostic Testing IS Indicated (IDSA / ACG Guidelines)

Stool evaluation should be performed promptly when any of the following clinical criteria are present:

Severe Illness : High fever (oral temperature ≥38.5°C / 101.3°F), severe volume depletion, orthostatic hypotension, or signs of systemic sepsis.

Dysentery / Bloody Diarrhea : Frank hematochezia, visible rectal blood, or bloody mucoid stools.

Prolonged Symptom Duration : Diarrhea persisting longer than 7 days without clinical improvement.

Vulnerable / High-Risk Hosts : Elderly patients (age ≥65 years), infants, severe underlying medical comorbidities (cirrhosis, end-stage renal disease, severe congestive heart failure), or immunocompromised hosts (HIV/AIDS with CD4 <200, solid organ transplant, active systemic chemotherapy, biologic immunosuppressive agents).

Public Health & Occupational Concerns : Commercial food handlers, healthcare workers, and daycare staff or attendees.

Recent Hospitalization or Antibiotic Exposure : Symptoms developing ≥48 hours after hospital admission or within 90 days of antimicrobial therapy (mandates testing for C. difficile ).

Diagnostic Modalities

Multiplex Molecular GI Stool PCR (GI Pathogen Panel) : Rapid, highly sensitive and specific syndromic nucleic acid amplification test (NAAT) detecting 15 to 22 common bacterial, viral, and parasitic targets within 1 to 4 hours. Preferred initial test in hospitalized or severely ill patients.

Conventional Stool Bacterial Culture : Detects Salmonella , Shigella , Campylobacter , and Yersinia . Requires specific request for Sorbitol-MacConkey (SMAC) agar to identify E. coli O157:H7 (which fails to ferment sorbitol, appearing as clear/white colonies).

Fecal Leukocytes and Fecal Lactoferrin : Qualitative or quantitative surrogate markers of mucosal inflammation that differentiate inflammatory dysentery from secretory or functional diarrhea.

Stool Ova and Parasites (O&P) Microscopic Exam : Recommended primarily for diarrhea persisting >14 days, wilderness water exposure, travel to endemic developing nations, or persistent diarrhea in immunocompromised hosts. Three separate stool specimens collected on consecutive days optimize diagnostic sensitivity.

Shiga Toxin-Producing E. Coli (STEC) & Hemolytic Uremic Syndrome (HUS)

Caution

CRITICAL CLINICAL PEARL: CONTRAINDICATION TO ANTIMICROBIALS & ANTIMOTILITY AGENTS IN STEC In any patient presenting with acute bloody diarrhea where Shiga toxin-producing Escherichia coli (STEC / E. coli O157:H7) is confirmed or strongly suspected, ANTIMICROBIAL THERAPY AND ANTIMOTILITY AGENTS (LOPERAMIDE) ARE STRICTLY CONTRAINDICATED ! Administration of antibiotics induces bacterial stress and triggers prophage lytic activation, causing massive, explosive release of preformed Shiga toxins (Stx1 and Stx2). This dramatically increases the incidence and severity of Hemolytic Uremic Syndrome (HUS) by up to 10-fold. Antimotility agents paralyze intestinal peristalsis, prolonging gut mucosal contact with Shiga toxins and facilitating systemic toxin absorption.

Pathophysiology of Hemolytic Uremic Syndrome

STEC is contracted through ingestion of undercooked ground beef, unpasteurized milk or apple cider, fecally contaminated water, or petting zoos.

Symptoms begin after a 2- to 8-day incubation period as non-bloody watery diarrhea with severe, agonizing, crampy abdominal pain. Within 24 to 72 hours, the stool turns grossly bloody (dysentery) in >90% of patients. A prominent clinical hallmark is the absence of high fever (patients are typically afebrile or have low-grade temperature <38.0°C), distinguishing STEC from Shigella or Campylobacter .

Systemic absorption of Shiga toxins (predominantly Stx2) leads to toxin binding to globotriaosylceramide (Gb3) receptors , which are densely expressed on vascular endothelial cells in renal glomeruli and the cerebral microvasculature.

Endothelial cell apoptosis and detachment expose thrombogenic subendothelial collagen, triggering widespread platelet microthrombi formation, capillary lumen narrowing, mechanical erythrocyte fragmentation, and glomerular ischemic necrosis.

The Classic HUS Triad

HUS typically develops 5 to 10 days after the onset of diarrhea (often just as gastrointestinal symptoms are improving):

Microangiopathic Hemolytic Anemia (MAHA) : Severe normocytic anemia with abundant schistocytes (helmet cells) on peripheral blood smear, elevated serum lactate dehydrogenase (LDH), indirect hyperbilirubinemia, reticulocytosis, and undetectable serum haptoglobin; direct Coombs test is negative.

Thrombocytopenia : Platelet consumption within microvascular thrombi, typically dropping platelets to <50,000/mcL. PT/INR and aPTT are normal (distinguishing HUS from disseminated intravascular coagulation [DIC]).

Acute Kidney Injury (AKI) : Oliguria or anuria, elevated serum creatinine, microscopic hematuria, and proteinuria.

Evidence-Based Management of STEC Infection

Immediate Discontinuation / Avoidance of Antibiotics and Loperamide .

Aggressive Early Intravenous Isotonic Fluid Resuscitation : Maintaining vigorous intravascular volume expansion during the initial diarrheal phase preserves renal capillary perfusion and has been shown to significantly attenuate the development of anuric renal failure and permanent dialysis dependence.

Close Outpatient or Inpatient Surveillance : Daily monitoring of complete blood count (CBC with differential and platelet count), serum creatinine, BUN, electrolytes, and urine output until 7 to 10 days after diarrhea onset.

Clostridioides Difficile Infection (CDI)

Clostridioides difficile (formerly Clostridium difficile ) is an anaerobic, spore-forming, toxin-producing Gram-positive rod that represents the leading cause of healthcare-associated and antibiotic-associated infectious diarrhea.

Risk Factors & Pathogenesis

Antimicrobial Exposure : The single greatest risk factor. Exposure to broad-spectrum antibiotics within the preceding 90 days disrupts the normal colonic microbial barrier (loss of colonization resistance). Highest risk agents include: fluoroquinolones, clindamycin, 3rd- and 4th-generation cephalosporins, carbapenems, and broad-spectrum beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam).

Host Factors : Age ≥65 years, recent hospitalization or skilled nursing facility residency, gastrointestinal surgery, underlying inflammatory bowel disease, immunocompromised status, and chronic acid suppression with proton pump inhibitors (PPIs).

Toxins : Pathogenic strains produce two potent exotoxins:

Toxin A (Enterotoxin) : Causes mucosal brush border disruption, fluid secretion, and mucosal inflammation.

Toxin B (Cytotoxin) : 10 times more potent than Toxin A; depolymerizes host cell actin filaments, causing colonocyte apoptosis, detachment, pseudomembrane formation, and mucosal necrosis.

Diagnostic Testing: Principles & Pitfalls

Test Selection Rule : Stool testing should ONLY be performed on patients with unexplained, new-onset loose or liquid stools (≥3 unformed stools in 24 hours) . Testing formed stool is strictly contraindicated because asymptomatic colonization occurs in up to 10% to 20% of hospitalized patients and up to 50% of long-term care residents. Never perform a "test of cure" following treatment, as stool PCR tests remain positive for months despite clinical cure.

Diagnostic Algorithm :

Two-Step Algorithm : Initial screening with Glutamate Dehydrogenase (GDH) antigen (highly sensitive marker of C. diff presence) combined with Toxin A/B Enzyme Immunoassay (EIA) (highly specific for active toxin production).

If both are positive: Confirmed active CDI.

If GDH is negative and Toxin EIA is negative: CDI excluded.

If discordant (GDH positive, Toxin EIA negative): Reflex to Nucleic Acid Amplification Test (NAAT / PCR) to determine whether a toxigenic gene ( tcdB ) is present, differentiating active low-toxin disease from asymptomatic colonization in clinical context.

Severity Stratification & First-Line Guideline Pharmacotherapy

According to official Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines:

Disease Severity Clinical & Laboratory Criteria First-Line Recommended Pharmacotherapy

Initial Episode: Non-Severe WBC <15,000 cells/mcL AND Serum Creatinine <1.5 mg/dL • Preferred First-Line : Oral Fidaxomicin 200 mg twice daily for 10 days ; • Alternative First-Line : Oral Vancomycin 125 mg four times daily for 10 days ; (Oral Metronidazole is NO LONGER recommended as first-line)

Initial Episode: Severe WBC ≥15,000 cells/mcL OR Serum Creatinine >1.5 mg/dL • Preferred First-Line : Oral Fidaxomicin 200 mg twice daily for 10 days ; • Alternative First-Line : Oral Vancomycin 125 mg four times daily for 10 days

Fulminant CDI Hypotension, septic shock, ileus, or toxic megacolon • Oral Vancomycin 500 mg QID (via NG tube if ileus) PLUS IV Metronidazole 500 mg Q8H ; • If ileus present, add Vancomycin retention enemas (500 mg in 100 mL saline PR Q6H); • Urgent surgical consult for subtotal colectomy or diverting loop ileostomy

Important

Why Fidaxomicin is Preferred over Vancomycin & Why Metronidazole is Deprecated :

Fidaxomicin is a narrow-spectrum macrocyclic antibiotic that selectively inhibits bacterial RNA polymerase. Because it specifically targets C. diff while sparing normal gut commensal anaerobes (especially Bacteroides species), it preserves colonization resistance and results in an ~50% lower rate of recurrent CDI compared to vancomycin.

Oral Vancomycin remains an excellent, accessible alternative. Note: Intravenous vancomycin is completely ineffective for CDI because it is not excreted into the intestinal lumen; it must be administered orally.

Oral Metronidazole is no longer recommended for initial episodes due to clear clinical trial evidence demonstrating significantly lower clinical cure rates and higher rates of treatment failure and disease recurrence compared to vancomycin and fidaxomicin. It is only considered if fidaxomicin and vancomycin are unavailable.

Management of Recurrent CDI

First Recurrence :

If oral vancomycin was used for the initial episode: Prescribe Oral Fidaxomicin 200 mg BID for 10 days (or extended-pulsed fidaxomicin).

If fidaxomicin was used initially: Prescribe a tapered and pulsed Oral Vancomycin regimen (e.g., 125 mg QID x 10-14d, then BID x 7d, then once daily x 7d, then every 2-3 days for 2-8 weeks).

Adjunctive Monoclonal Antibody: Bezlotoxumab (single IV infusion 10 mg/kg), a human monoclonal antibody targeting C. diff Toxin B, can be co-administered with standard antibiotics to prevent further recurrences in patients at high risk (age ≥65, immunocompromised, severe initial CDI).

Second or Subsequent Recurrence (≥2 Recurrences) :

Fecal Microbiota Transplantation (FMT) or FDA-approved live biotherapeutic products (e.g., fecal microbiota spores, Firmicutes spores / SER-109 / VOWST) are standard of care, restoring gut microbiome biodiversity with cure rates exceeding 85% to 90%.

Traveler's Diarrhea (TD) & Geographic Antimicrobial Stewardship

Traveler's diarrhea is defined as the passage of ≥3 unformed stools in 24 hours accompanied by at least one enteric symptom (abdominal cramps, nausea, vomiting, fever, fecal urgency) occurring in an individual traveling from an industrialized country to a resource-limited destination.

Etiology & Geographic Distribution

Bacterial Pathogens (80% to 90%) : Enterotoxigenic E. coli (ETEC) is the most common cause worldwide (50% to 80% of bacterial cases), utilizing plasmid-encoded heat-labile (LT) and/or heat-stable (ST) toxins to hyperactivate enterocyte adenylate and guanylate cyclases. Other bacterial culprits include Campylobacter jejuni , Shigella , and Salmonella .

Geographic Resistance Patterns : In South Asia and Southeast Asia (India, Thailand, Nepal) , fluoroquinolone-resistant Campylobacter exceeds 80% to 90% , rendering ciprofloxacin completely ineffective. In Latin America, the Caribbean, and Africa, ETEC and other pathogens remain moderately susceptible to fluoroquinolones.

Clinical Staging & Stepwise Management

Mild TD (Tolerable, does not interfere with planned activities) :

Pharmacotherapy: Oral Rehydration Therapy alone. Loperamide or bismuth subsalicylate (Pepto-Bismol, 524 mg chewable tablets every 30 to 60 minutes, max 8 doses/day) may be used for symptomatic relief. Antibiotics are NOT recommended .

Moderate TD (Distressing, interferes with planned activities) :

Pharmacotherapy: Loperamide as monotherapy or combined with a single dose of an antibiotic.

Severe TD (Incapacitating, prevents all activity, or any gross dysentery / bloody stools) :

First-Line for Dysentery, Bloody Stools, High Fever, or Travel to South/Southeast Asia :

Oral Azithromycin : 1,000 mg as a single oral dose , OR 500 mg orally once daily for 3 days .

Azithromycin is the gold-standard drug of choice for traveler's diarrhea in Southeast Asia, overcoming fluoroquinolone resistance and effectively treating invasive Campylobacter and Shigella .

Alternative for Non-Dysenteric Watery Diarrhea in Latin America / Africa :

Oral Ciprofloxacin (750 mg single dose or 500 mg BID x 3 days) or Levofloxacin (500 mg single dose).

Oral Rifaximin (200 mg TID for 3 days): Non-absorbable rifamycin derivative. Highly effective for non-invasive ETEC watery diarrhea, but strictly contraindicated if fever or bloody stools are present because it lacks systemic bioavailability and fails to treat invasive pathogens ( Campylobacter , Salmonella , Shigella ).

Oral Rehydration Therapy & Antimotility Safety Rules
Oral Rehydration Solution (ORS) Science

The cornerstone of all diarrheal management is fluid and electrolyte replacement. Intestinal fluid absorption depends on the sodium-glucose cotransporter (SGLT-1) located on the brush border membrane of mature small intestinal villus enterocytes.

Even during profound toxin-mediated secretory diarrhea (e.g., cholera, ETEC), where cyclic nucleotides shut down electroneutral sodium chloride absorption and stimulate massive chloride secretion, SGLT-1 remains fully operational .

Coupling 1 molecule of sodium to 1 molecule of glucose allows active cotransport into enterocytes, generating an osmotic gradient that pulls water from the gut lumen into the circulation.

WHO Reduced-Osmolarity ORS Formulation (Osmolarity 245 mOsm/L):

Sodium: 75 mEq/L
Glucose: 75 mmol/L (13.5 g/L)
Potassium: 20 mEq/L
Chloride: 65 mEq/L
Citrate: 10 mmol/L (2.9 g/L)

Clinical Pitfall : Commercial sodas, fruit juices, and sports drinks have excessive osmolarity (>400-600 mOsm/L) and low sodium concentrations (<20 mEq/L), which exacerbate osmotic diarrhea and can precipitate hyponatremia.

Loperamide: Clinical Mechanism, Dosing & Absolute Contraindications

Mechanism of Action : Peripheral mu-opioid receptor agonist in the myenteric (Auerbach) plexus of the intestinal wall. It slows circular and longitudinal intestinal peristalsis, increases gastrointestinal transit time, enhances fluid and electrolyte mucosal absorption, and increases anal sphincter resting tone.

Adult Dosing : Initial dose of 4 mg orally, followed by 2 mg after each unformed stool (maximum OTC dose: 8 mg/day; maximum prescription dose: 16 mg/day) for no more than 48 hours.

Absolute Contraindications :

Bloody diarrhea (gross hematochezia / dysentery) ;
High fever (temperature ≥38.5°C / 101.3°F) or signs of systemic toxicity;
Confirmed or suspected Shiga toxin-producing E. coli (STEC) (precipitates severe HUS);

Active Clostridioides difficile infection (precipitates toxic megacolon and bowel perforation).